Active Pharmaceutical Ingredients (APIs) Market - Global Outlook & Forecast 2023-2028

Description

The global active pharmaceutical ingredients (API) market is expected to grow at a CAGR of 6.67% from 2022 to 2028.

MARKET TRENDS & DRIVERS

Reshaping the Pharmaceutical API Industry with Digital Transformation

Digital Transformation has allowed the active pharmaceutical ingredients (API) market to reshape itself to optimize production, streamline processes and reduce costs. By embracing the digital revolution, API manufacturers and suppliers can leverage advances in automated workflows, AI-enabled production management, and increased predictive analytics capabilities for data-driven decision-making. Additionally, the cloud-based infrastructure allows API-focused stakeholders to store, manage and use their data. At the same time, the increasing affordability of automation and other digital technologies helps to create a more efficient and cost-effective API supply chain more easily. Together, these advancements have enabled the pharmaceutical API industry to become more agile, responsive, and cost-efficient - unlocking new possibilities for product innovation and providing customers with a better overall experience.

Rising Demand for Novel APIs

The rising demand for novel APIs is due to the increasing need for newer, more specialized drugs to treat complex diseases, illnesses, and medical conditions. Novel APIs are developed using advanced biotechnologies and advanced synthesis techniques to create more effective drugs that provide better treatment than existing drugs. The growing demand for novel APIs is that they present several advantages over existing drugs, including improved safety, efficacy, and cost-effectiveness. Moreover, they can be used to treat rare diseases that current drugs cannot treat and to produce new therapies for existing diseases.

Technological Advancements API Manufacturing

The technological advancements in manufacturing in the active pharmaceutical ingredients (API) market have helped improve API quality, increase production efficiency, reduce costs, and ensure environmental protection. New technologies for API manufacturing include continuous processing and computerization of operations, which enable large-scale, cost-effective, and efficient production. Automated machines, computer-controlled process description (CPD) systems, and digital manufacturing systems are now being used to increase the accuracy of API formulation, improve overall efficiency, and reduce manual labor requirements. In addition, new technological advancements such as micronization techniques, nanotechnology, and crystallization techniques greatly improve API quality while increasing overall production speeds. Finally, new waste management methods, such as liquid waste treatments, have also significantly improved API manufacturing processes, as well as standards of environmental protection.

Growing Importance & Demand for Generic Drugs

Over recent years, the growing importance and demand for generic drugs have increased tremendously. This is mainly due to the cost savings they offer, as generic drugs typically cost 30-80% less than other brand-name drugs. Moreover, generic drugs are often the only option for patients who cannot afford expensive brand-name drugs. As such, generic drugs have become increasingly popular among consumers seeking affordable healthcare solutions. Additionally, generic drugs have become more widely available due to government programs like Medicaid and Medicare. These government-sponsored programs help to make generic drugs more accessible to those who need them. Furthermore, the increased demand for generic drugs has led to yet another significant development in the pharmaceutical industry: the formation of API manufacturers. These companies specialize in the production of APIs that are designed explicitly for generic medications. Creating APIs specifically tailored to generics can provide a cost-effective alternative to more expensive original drugs. As a result, manufacturers in the active pharmaceutical ingredients (API) market have become an essential component of the generic drug supply chain.

SEGMENTATION INSIGHTS

INSIGHTS BY MOLECULE TYPE

The global active pharmaceutical ingredients (API) market by molecule type is classified as large and small. This differentiation not only considers the size of the molecule but also how the molecules are made, their behavior, drug delivery, and mode of delivery. A small molecule API refers to an organic compound with a size of about 1 nm, which assists in regulating biological processes. Small molecules may be orally delivered, and the body is most likely to consume them. They possess the characteristics of rapid infusibility due to their small size, which enables them to reach the intercellular site of action. Small molecules have long been the basis for drug development. They are easily digested or absorbed into the bloodstream.

Segmentation by Molecule Type

Small Molecule/ Chemical API
Large Molecule/ Biological API

INSIGHTS BY THERAPY AREA

The cardiovascular therapy area dominated the global active pharmaceutical ingredients (API) market, accounting for a share of over 19% in 2022. Cardiovascular APIs are manufactured by companies involved in drug manufacturing for cardiovascular diseases. Manufacturers producing hypertensive drugs for people with high blood pressure drive the market's growth. Cardiovascular disease is a major cause of death and disability worldwide and is a major medical research and development focus. Pharmaceutical interventions are an important part of treatment for cardiovascular conditions, particularly when managing risk factors such as high blood pressure, high cholesterol, and diabetes. APIs are used to create medicines targeting specific aspects of the condition to achieve effective cardiovascular therapy.

Segmentation by Therapy Area

Cardiovascular
Oncology
Neurology
Anti-infectives
Endocrinology
Pulmonology
Others

INSIGHTS BY MANUFACTURERS TYPE

Based on the type of manufacturing process that an API-producing company opts for, the active pharmaceutical ingredients (API) market is segmented into captive and merchant markets. The captive market includes APIs produced by manufacturers in-house for their own needs, while the merchant market for APIs includes APIs manufactured by third parties. There are a lot of benefits and shortcomings of producing APIs in-house. COVID-19 has fueled the need for producing APIs in-house rather than outsourcing due to disruptions in the supply chain in China.

Segmentation by Manufacturers Type

Captive
Merchant

INSIGHTS BY BRAND

The patented/ innovative APIs segment accounted for a higher global active pharmaceutical ingredients (API) market in 2022. The use of patented or innovative active pharmaceutical ingredients (API) has become increasingly important in the pharmaceutical industry in recent years. Patented API can give a pharmaceutical company a competitive advantage through its exclusive access to the API, enabling it to sell products at higher margins and have a greater market share. API innovation is a necessary component of the pharmaceutical industry since it advances the development of new and improved pharmaceutical products that can benefit patients

Segmentation by Brand

Patented/ Innovative API
Generic API

INSIGHTS BY POTENCY

Active pharmaceutical ingredients (APIs) are essential components in producing pharmaceutical products. They are the active components in medicines that are responsible for the desired therapeutic effect. In recent years, the potency of APIs has become increasingly important for producing safe and effective medicines. Non-potent active pharmaceutical ingredients (NAPIs) are substances used as active ingredients in pharmaceuticals but do not possess the same potency as their potent counterparts (APIs). NAPIs are typically combined with APIs to enhance the drugs' therapeutic effect or reduce their toxicity. Low-potency NAPIs are generally considered safe for human consumption and are used to provide minor therapeutic benefits. The global non-potent active pharmaceutical ingredients (API) market is expected to grow at a CAGR of over 6% during the forecast period.

Segmentation by Potency

Non-potent API
Highly Potent API

GEOGRAPHICAL ANALYSIS

North America is one of the largest global active pharmaceutical ingredients (API) markets, accounting for over 41% share in 2022. The region has seen a steady growth in the demand for APIs, driven primarily by the increasing prevalence of chronic diseases, the rising demand for generic drugs, and the rapid development of the pharmaceutical industry. The increasing number of chronic diseases in North America has been a major factor driving the demand for APIs. According to the Centers for Disease Control and Prevention (CDC), around half of the adults in the U.S. suffer from at least one chronic disease. This has led to an increase in the use of prescription drugs, which in turn has led to an increase in the demand for APIs.

Segmentation by Geography

North America
- The U.S.
- Canada
APAC
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Singapore
Europe
- Germany
- The U.K.
- Russia
- France
- Spain
- Italy
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- South Africa

COMPETITIVE LANDSCAPE

The active pharmaceutical ingredients (API) market is concentrated, competitive, and characterized by numerous global and domestic vendors across geographies. AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, Eli Lilly and Company, GSK, Merck KGaA, Novartis, Pfizer, Sanofi, Sun Pharmaceuticals, and Viatris are the prominent vendors in the global active pharmaceutical ingredients (API) market. These companies are always at the forefront of delivering high-quality APIs for domestic and international pharmaceutical manufacturers. They also invest in considerable R&D activities to offer a competitive product line.

Key Company Profiles

AbbVie
Boehringer Ingelheim
Bristol-Myers Squibb Company
Cipla
Eli Lilly and Company
GSK
Merck KGaA
Novartis
Pfizer
Sanofi
Sun Pharmaceutical Industries
Viatris

Other Prominent Vendors

Abbott
Albemarle Corporation
Amgen
Aurobindo Pharma
BASF Corporation
Biocon
Dr. Reddy's Laboratories Ltd.
Teva Pharmaceuticals Industries
F. Hoffmann-La Roche
GLENMARK PHARMACEUTICALS LTD.
Lupin
Shenzhen Hepalink Pharmaceutical Group

KEY QUESTIONS ANSWERED:

1. How big is the active pharmaceutical ingredients (API) market?
2. What is the growth rate of the global active pharmaceutical ingredients (API) market?
3. What are the growing trends in the active pharmaceutical ingredients (API) market?
4. Which region holds the most significant global active pharmaceutical ingredients (API) market share?
5. Who are the key players in the global active pharmaceutical ingredients (API) market?

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
- 4.3.1 MARKET SEGMENTATION BY MOLECULE TYPE
- 4.3.2 MARKET SEGMENTATION BY THERAPY AREA
- 4.3.3 MARKET SEGMENTATION BY MANUFACTURER TYPE
- 4.3.4 MARKET SEGMENTATION BY BRAND
- 4.3.5 MARKET SEGMENTATION BY POTENCY
- 4.3.6 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 PREMIUM INSIGHTS

7.1 OVERVIEW
- 7.1.1 GEOGRAPHY INSIGHTS
- 7.1.2 MOLECULE TYPE SEGMENTATION INSIGHTS
- 7.1.3 THERAPY AREA SEGMENTATION INSIGHTS
- 7.1.4 MANUFACTURER TYPE SEGMENTATION INSIGHTS
- 7.1.5 BRAND SEGMENTATION INSIGHTS
- 7.1.6 POTENCY SEGMENTATION INSIGHTS

8 INTRODUCTION

8.1 OVERVIEW
- 8.1.1 IMPACT OF COVID-19

9 MARKET OPPORTUNITIES & TRENDS

9.1 DIGITAL TRANSFORMATION OF PHARMACEUTICAL API INDUSTRY
9.2 INCREASED ADOPTION OF BIOSIMILARS
9.3 DEMAND FOR NOVEL APIS

10 MARKET GROWTH ENABLERS

10.1 TECHNOLOGICAL ADVANCES IN API MANUFACTURING
10.2 DEMAND FOR GENERIC DRUGS
10.3 GROWTH OF PHARMACEUTICAL INDUSTRY
10.4 INCREASED API OUTSOURCING OPERATIONS

11 MARKET RESTRAINTS

11.1 STRINGENT GOVERNMENT REGULATIONS
11.2 LOW PROFIT MARGINS & HIGH API-MANUFACTURING COSTS
11.3 ANALYTICAL CHALLENGES IN TESTING PROCESSES

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
- 12.3.1 MARKET BY MOLECULE TYPE
- 12.3.2 MARKET BY THERAPY AREA
- 12.3.3 MARKET BY MANUFACTURER TYPE
- 12.3.4 MARKET BY BRAND
- 12.3.5 MARKET BY POTENCY
- 12.3.6 MARKET BY GEOGRAPHY
12.4 FIVE FORCES ANALYSIS
- 12.4.1 THREAT OF NEW ENTRANTS
- 12.4.2 BARGAINING POWER OF SUPPLIERS
- 12.4.3 BARGAINING POWER OF BUYERS
- 12.4.4 THREAT OF SUBSTITUTES
- 12.4.5 COMPETITIVE RIVALRY

13 MOLECULE TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 SMALL MOLECULES/CHEMICAL APIS
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.3.3 SMALL MOLECULES/CHEMICAL APIS BY GEOGRAPHY
13.4 LARGE MOLECULES/BIOLOGICAL APIS
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.4.3 LARGE MOLECULES/BIOLOGICAL APIS BY GEOGRAPHY

14 THERAPY AREA

14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 CARDIOVASCULAR
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.3.3 CARDIOVASCULAR BY GEOGRAPHY
14.4 ONCOLOGY
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.4.3 ONCOLOGY BY GEOGRAPHY
14.5 NEUROLOGY
- 14.5.1 MARKET OVERVIEW
- 14.5.2 MARKET SIZE & FORECAST
- 14.5.3 NEUROLOGY BY GEOGRAPHY
14.6 ANTI-INFECTIVES
- 14.6.1 MARKET OVERVIEW
- 14.6.2 MARKET SIZE & FORECAST
- 14.6.3 ANTI-INFECTIVES BY GEOGRAPHY
14.7 ENDOCRINOLOGY
- 14.7.1 MARKET OVERVIEW
- 14.7.2 MARKET SIZE & FORECAST
- 14.7.3 ENDOCRINOLOGY BY GEOGRAPHY
14.8 PULMONOLOGY
- 14.8.1 MARKET OVERVIEW
- 14.8.2 MARKET SIZE & FORECAST
- 14.8.3 PULMONOLOGY BY GEOGRAPHY
14.9 OTHER THERAPY AREAS
- 14.9.1 MARKET OVERVIEW
- 14.9.2 MARKET SIZE & FORECAST
- 14.9.3 OTHER THERAPY AREAS BY GEOGRAPHY

15 MANUFACTURER TYPE

15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 CAPTIVE
- 15.3.1 MARKET OVERVIEW
- 15.3.2 MARKET SIZE & FORECAST
- 15.3.3 CAPTIVE BY GEOGRAPHY
15.4 MERCHANT
- 15.4.1 MARKET OVERVIEW
- 15.4.2 MARKET SIZE & FORECAST
- 15.4.3 MERCHANT BY GEOGRAPHY

16 BRAND

16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 PATENTED/INNOVATIVE APIS
- 16.3.1 MARKET OVERVIEW
- 16.3.2 MARKET SIZE & FORECAST
- 16.3.3 PATENTED/INNOVATIVE APIS BY GEOGRAPHY
16.4 GENERIC APIS
- 16.4.1 MARKET OVERVIEW
- 16.4.2 MARKET SIZE & FORECAST
- 16.4.3 GENERIC APIS BY GEOGRAPHY

17 POTENCY

17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 NON-POTENT APIS
- 17.3.1 MARKET OVERVIEW
- 17.3.2 MARKET SIZE & FORECAST
- 17.3.3 NON-POTENT APIS BY GEOGRAPHY
17.4 HIGHLY POTENT APIS
- 17.4.1 MARKET OVERVIEW
- 17.4.2 MARKET SIZE & FORECAST
- 17.4.3 HIGHLY POTENT APIS BY GEOGRAPHY

18 GEOGRAPHY

18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 GEOGRAPHIC OVERVIEW

19 NORTH AMERICA

19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
- 19.2.1 NORTH AMERICA: MARKET BY MOLECULE TYPE
- 19.2.2 NORTH AMERICA: MARKET BY THERAPY AREA
- 19.2.3 NORTH AMERICA: MARKET BY MANUFACTURER TYPE
- 19.2.4 NORTH AMERICA: MARKET BY BRAND
- 19.2.5 NORTH AMERICA: MARKET BY POTENCY
19.3 KEY COUNTRIES
- 19.3.1 US: MARKET SIZE & FORECAST
- 19.3.2 CANADA: MARKET SIZE & FORECAST

20 APAC

20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
- 20.2.1 APAC: MARKET BY MOLECULE TYPE
- 20.2.2 APAC: MARKET BY THERAPY AREA
- 20.2.3 APAC: MARKET BY MANUFACTURER TYPE
- 20.2.4 APAC: MARKET BY BRAND
- 20.2.5 APAC: MARKET BY POTENCY
20.3 KEY COUNTRIES
- 20.3.1 CHINA: MARKET SIZE & FORECAST
- 20.3.2 INDIA: MARKET SIZE & FORECAST
- 20.3.3 JAPAN: MARKET SIZE & FORECAST
- 20.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
- 20.3.5 AUSTRALIA: MARKET SIZE & FORECAST
- 20.3.6 INDONESIA: MARKET SIZE & FORECAST
- 20.3.7 SINGAPORE: MARKET SIZE & FORECAST

21 EUROPE

21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
- 21.2.1 EUROPE: MARKET BY MOLECULE TYPE
- 21.2.2 EUROPE: MARKET BY THERAPY AREA
- 21.2.3 EUROPE: MARKET BY MANUFACTURER TYPE
- 21.2.4 EUROPE: MARKET BY BRAND
- 21.2.5 EUROPE: MARKET BY POTENCY
21.3 KEY COUNTRIES
- 21.3.1 GERMANY: MARKET SIZE & FORECAST
- 21.3.2 UK: MARKET SIZE & FORECAST
- 21.3.3 RUSSIA: MARKET SIZE & FORECAST
- 21.3.4 FRANCE: MARKET SIZE & FORECAST
- 21.3.5 SPAIN: MARKET SIZE & FORECAST
- 21.3.6 ITALY: MARKET SIZE & FORECAST

22 LATIN AMERICA

22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
- 22.2.1 LATIN AMERICA: MARKET BY MOLECULE TYPE
- 22.2.2 LATIN AMERICA: MARKET BY THERAPY AREA
- 22.2.3 LATIN AMERICA: MARKET BY MANUFACTURER TYPE
- 22.2.4 LATIN AMERICA: MARKET BY BRAND
- 22.2.5 LATIN AMERICA: MARKET BY POTENCY
22.3 KEY COUNTRIES
- 22.3.1 BRAZIL: MARKET SIZE & FORECAST
- 22.3.2 MEXICO: MARKET SIZE & FORECAST
- 22.3.3 ARGENTINA: MARKET SIZE & FORECAST

23 MIDDLE EAST & AFRICA

23.1 MARKET OVERVIEW
23.2 MARKET SIZE & FORECAST
- 23.2.1 MIDDLE EAST & AFRICA: MARKET BY MOLECULE TYPE
- 23.2.2 MIDDLE EAST & AFRICA: MARKET BY THERAPY AREA
- 23.2.3 MIDDLE EAST & AFRICA: MARKET BY MANUFACTURER TYPE
- 23.2.4 MIDDLE EAST & AFRICA: MARKET BY BRAND
- 23.2.5 MIDDLE EAST & AFRICA: MARKET BY POTENCY
23.3 KEY COUNTRIES
- 23.3.1 TURKEY: MARKET SIZE & FORECAST
- 23.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
- 23.3.3 UAE: MARKET SIZE & FORECAST
- 23.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST

24 COMPETITIVE LANDSCAPE

24.1 COMPETITION OVERVIEW
- 24.1.1 RECENT KEY ACTIVITIES IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
24.2 MARKET SHARE ANALYSIS
- 24.2.1 ABBVIE
- 24.2.2 BOEHRINGER INGELHEIM
- 24.2.3 BRISTOL-MYERS SQUIBB COMPANY
- 24.2.4 CIPLA
- 24.2.5 ELI LILLY AND COMPANY
- 24.2.6 GSK
- 24.2.7 MERCK KGAA
- 24.2.8 NOVARTIS
- 24.2.9 PFIZER
- 24.2.10 SANOFI
- 24.2.11 SUN PHARMACEUTICAL INDUSTRIES
- 24.2.12 VIATRIS

25 KEY COMPANY PROFILES

25.1 ABBVIE
- 25.1.1 BUSINESS OVERVIEW
- 25.1.2 PRODUCT OFFERINGS
- 25.1.3 KEY STRATEGIES
- 25.1.4 KEY STRENGTHS
- 25.1.5 KEY OPPORTUNITIES
25.2 BOEHRINGER INGELHEIM
- 25.2.1 BUSINESS OVERVIEW
- 25.2.2 PRODUCT OFFERINGS
- 25.2.3 KEY STRATEGIES
- 25.2.4 KEY STRENGTHS
- 25.2.5 KEY OPPORTUNITIES
25.3 BRISTOL-MYERS SQUIBB COMPANY
- 25.3.1 BUSINESS OVERVIEW
- 25.3.2 PRODUCT OFFERINGS
- 25.3.3 KEY STRATEGIES
- 25.3.4 KEY STRENGTHS
- 25.3.5 KEY OPPORTUNITIES
25.4 CIPLA
- 25.4.1 BUSINESS OVERVIEW
- 25.4.2 PRODUCT OFFERINGS
- 25.4.3 KEY STRATEGIES
- 25.4.4 KEY STRENGTHS
- 25.4.5 KEY OPPORTUNITIES
25.5 ELI LILLY AND COMPANY
- 25.5.1 BUSINESS OVERVIEW
- 25.5.2 PRODUCT OFFERINGS
- 25.5.3 KEY STRATEGIES
- 25.5.4 KEY STRENGTHS
- 25.5.5 KEY OPPORTUNITIES
25.6 GSK
- 25.6.1 BUSINESS OVERVIEW
- 25.6.2 PRODUCT OFFERINGS
- 25.6.3 KEY STRATEGIES
- 25.6.4 KEY STRENGTHS
- 25.6.5 KEY OPPORTUNITIES
25.7 MERCK KGAA
- 25.7.1 BUSINESS OVERVIEW
- 25.7.2 PRODUCT OFFERINGS
- 25.7.3 KEY STRATEGIES
- 25.7.4 KEY STRENGTHS
- 25.7.5 KEY OPPORTUNITIES
25.8 NOVARTIS
- 25.8.1 BUSINESS OVERVIEW
- 25.8.2 PRODUCT OFFERINGS
- 25.8.3 KEY STRATEGIES
- 25.8.4 KEY STRENGTHS
- 25.8.5 KEY OPPORTUNITIES
25.9 PFIZER
- 25.9.1 BUSINESS OVERVIEW
- 25.9.2 PRODUCT OFFERINGS
- 25.9.3 KEY STRATEGIES
- 25.9.4 KEY STRENGTHS
- 25.9.5 KEY OPPORTUNITIES
25.10 SANOFI
- 25.10.1 BUSINESS OVERVIEW
- 25.10.2 PRODUCT OFFERINGS
- 25.10.3 KEY STRATEGIES
- 25.10.4 KEY STRENGTHS
- 25.10.5 KEY OPPORTUNITIES
25.11 SUN PHARMACEUTICAL INDUSTRIES
- 25.11.1 BUSINESS OVERVIEW
- 25.11.2 PRODUCT OFFERINGS
- 25.11.3 KEY STRATEGIES
- 25.11.4 KEY STRENGTHS
- 25.11.5 KEY OPPORTUNITIES
25.12 VIATRIS
- 25.12.1 BUSINESS OVERVIEW
- 25.12.2 PRODUCT OFFERINGS
- 25.12.3 KEY STRATEGIES
- 25.12.4 KEY STRENGTHS
- 25.12.5 KEY OPPORTUNITIES

26 OTHER PROMINENT VENDORS

26.1 ABBOTT
- 26.1.1 BUSINESS OVERVIEW
- 26.1.2 KEY HIGHLIGHTS
26.2 ALBEMARLE CORPORATION
- 26.2.1 BUSINESS OVERVIEW
- 26.2.2 KEY HIGHLIGHTS
26.3 AMGEN
- 26.3.1 BUSINESS OVERVIEW
- 26.3.2 KEY HIGHLIGHTS
26.4 AUROBINDO PHARMA
- 26.4.1 BUSINESS OVERVIEW
- 26.4.2 KEY HIGHLIGHTS
26.5 BASF CORPORATION
- 26.5.1 BUSINESS OVERVIEW
- 26.5.2 KEY HIGHLIGHTS
26.6 BIOCON
- 26.6.1 BUSINESS OVERVIEW
- 26.6.2 KEY HIGHLIGHTS
26.7 DR. REDDY'S LABORATORIES
- 26.7.1 BUSINESS OVERVIEW
- 26.7.2 KEY HIGHLIGHTS
26.8 TEVA PHARMACEUTICAL INDUSTRIES
- 26.8.1 BUSINESS OVERVIEW
- 26.8.2 KEY HIGHLIGHTS
26.9 F. HOFFMANN-LA ROCHE
- 26.9.1 BUSINESS OVERVIEW
- 26.9.2 KEY HIGHLIGHTS
26.10 GLENMARK PHARMACEUTICALS
- 26.10.1 BUSINESS OVERVIEW
- 26.10.2 KEY HIGHLIGHTS
26.11 LUPIN
- 26.11.1 BUSINESS OVERVIEW
- 26.11.2 KEY HIGHLIGHTS
26.12 SHENZHEN HEPALINK PHARMACEUTICAL GROUP
- 26.12.1 BUSINESS OVERVIEW
- 26.12.2 KEY HIGHLIGHTS

27 REPORT SUMMARY

27.1 KEY TAKEAWAYS
27.2 STRATEGIC RECOMMENDATIONS

28 QUANTITATIVE SUMMARY

28.1 MARKET BY MOLECULE TYPE
- 28.1.1 NORTH AMERICA: MARKET BY MOLECULE TYPE
- 28.1.2 APAC: MARKET BY MOLECULE TYPE
- 28.1.3 EUROPE: MARKET BY MOLECULE TYPE
- 28.1.4 LATIN AMERICA: MARKET BY MOLECULE TYPE
- 28.1.5 MIDDLE EAST & AFRICA: MARKET BY MOLECULE TYPE
28.2 MARKET BY THERAPY AREA
- 28.2.1 NORTH AMERICA: MARKET BY THERAPY AREA
- 28.2.2 APAC: MARKET BY THERAPY AREA
- 28.2.3 EUROPE: MARKET BY THERAPY AREA
- 28.2.4 LATIN AMERICA: MARKET BY THERAPY AREA SEGMENTATION
- 28.2.5 MIDDLE EAST & AFRICA: MARKET BY THERAPY AREA
28.3 MARKET BY MANUFACTURER TYPE
- 28.3.1 NORTH AMERICA: MARKET BY MANUFACTURER TYPE SEGMENTATION
- 28.3.2 APAC: MARKET BY MANUFACTURER TYPE
- 28.3.3 EUROPE: MARKET BY MANUFACTURER TYPE SEGMENTATION
- 28.3.4 LATIN AMERICA: MARKET BY MANUFACTURER TYPE SEGMENTATION
- 28.3.5 MIDDLE EAST & AFRICA: MARKET BY MANUFACTURER TYPE
28.4 MARKET BY BRAND
- 28.4.1 NORTH AMERICA: MARKET BY BRAND
- 28.4.2 APAC: MARKET BY BRAND
- 28.4.3 EUROPE: MARKET BY BRAND
- 28.4.4 LATIN AMERICA: MARKET BY BRAND
- 28.4.5 MIDDLE EAST & AFRICA: MARKET BY BRAND
28.5 MARKET BY POTENCY
- 28.5.1 NORTH AMERICA: MARKET BY POTENCY
- 28.5.2 APAC: MARKET BY POTENCY
- 28.5.3 EUROPE: MARKET BY POTENCY
- 28.5.4 LATIN AMERICA: MARKET BY POTENCY SEGMENTATION
- 28.5.5 MIDDLE EAST & AFRICA: MARKET BY POTENCY
28.6 MARKET BY GEOGRAPHY
- 28.6.1 SMALL MOLECULES/CHEMICAL APIS BY GEOGRAPHY
- 28.6.2 LARGE MOLECULES/BIOLOGICAL APIS BY GEOGRAPHY
- 28.6.3 CARDIOVASCULAR BY GEOGRAPHY
- 28.6.4 ONCOLOGY BY GEOGRAPHY
- 28.6.5 NEUROLOGY BY GEOGRAPHY
- 28.6.6 ANTI-INFECTIVES BY GEOGRAPHY
- 28.6.7 ENDOCRINOLOGY BY GEOGRAPHY
- 28.6.8 PULMONOLOGY BY GEOGRAPHY
- 28.6.9 OTHER THERAPY AREAS BY GEOGRAPHY
- 28.6.10 CAPTIVE BY GEOGRAPHY
- 28.6.11 MERCHANT BY GEOGRAPHY
- 28.6.12 PATENTED/INNOVATIVE APIS BY GEOGRAPHY
- 28.6.13 GENERIC APIS BY GEOGRAPHY
- 28.6.14 NON-POTENT APIS BY GEOGRAPHY
- 28.6.15 HIGHLY POTENT APIS BY GEOGRAPHY

29 APPENDIX

29.1 ABBREVIATIONS